Ingreso de fabricantes de vacunas infographic
El gráfico muestra el ingeeso más reciente de productores selectos de vacunas contra coronavirus.


Utilidades extraordinarias de los fabricantes de vacunas

By Duncan Mil

May 11, 2021 - Los cuatro fabricantes líderes de vacunas han aumentado sus utilidades desde el lanzamiento de la vacuna contra coronavirus, impulsadas por
cerca de $18.500 millones de financiamiento gubernamental, público y privado.

In total, governments and not-for-profit organisations have provided $4.59 billion, according to science data analytics company Airfinity. Private funding has provided around $13.91 billion.

AstraZeneca/Oxford University has received over $11.5 billion, and Johnson & Johnson has scooped up $1.1 billion. Almost $3.2bn has gone to Pfizer/BioNTech, while Moderna has received $2.68 billion.

Pfizer expects 2021 revenue of between $44 billion and $46 billion, with profits of at least $14 billion, split 50-50 between Pfizer and its German partner BioNTech.

Moderna’s forecast for 2021 is for revenue of $16 billion, overwhelmingly from vaccine sales.

Johnson & Johnson has said it will provide the vaccine on a not-for-profit basis as long as the world continues suffering from the pandemic. However, even after the pandemic has passed, people will need to receive booster shots to protect themselves from new variants.

PUBLISHED: 11/05/2021; STORY: Graphic News